NLS Pharmaceutics (NLSP) Competitors $1.96 -0.03 (-1.51%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$1.92 -0.04 (-1.99%) As of 09/5/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock NLSP vs. ITRM, KZR, CASI, ASBP, CLSD, PMN, DARE, TENX, BCAB, and MIRAShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Iterum Therapeutics (ITRM), Kezar Life Sciences (KZR), CASI Pharmaceuticals (CASI), Aspire Biopharma (ASBP), Clearside Biomedical (CLSD), Promis Neurosciences (PMN), Dare Bioscience (DARE), Tenax Therapeutics (TENX), BioAtla (BCAB), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. Its Competitors Iterum Therapeutics Kezar Life Sciences CASI Pharmaceuticals Aspire Biopharma Clearside Biomedical Promis Neurosciences Dare Bioscience Tenax Therapeutics BioAtla MIRA Pharmaceuticals Iterum Therapeutics (NASDAQ:ITRM) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings. Which has more volatility and risk, ITRM or NLSP? Iterum Therapeutics has a beta of 3.04, meaning that its stock price is 204% more volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Is ITRM or NLSP more profitable? Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -65.01% NLS Pharmaceutics N/A N/A N/A Do analysts rate ITRM or NLSP? Iterum Therapeutics currently has a consensus price target of $9.00, suggesting a potential upside of 1,227.04%. Given Iterum Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Iterum Therapeutics is more favorable than NLS Pharmaceutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NLS Pharmaceutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings and valuation, ITRM or NLSP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$24.77M-$0.85-0.80NLS PharmaceuticsN/AN/A-$1.98MN/AN/A Do institutionals and insiders have more ownership in ITRM or NLSP? 9.2% of Iterum Therapeutics shares are held by institutional investors. 2.4% of Iterum Therapeutics shares are held by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer ITRM or NLSP? In the previous week, NLS Pharmaceutics had 2 more articles in the media than Iterum Therapeutics. MarketBeat recorded 4 mentions for NLS Pharmaceutics and 2 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 1.04 beat NLS Pharmaceutics' score of 0.30 indicating that Iterum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iterum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NLS Pharmaceutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryIterum Therapeutics beats NLS Pharmaceutics on 6 of the 10 factors compared between the two stocks. Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NLSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.05M$2.59B$5.81B$9.91BDividend YieldN/A50.06%6.70%4.52%P/E RatioN/A23.3476.2926.13Price / SalesN/A569.60529.70172.90Price / CashN/A166.6036.9959.28Price / Book-5.305.5011.486.09Net Income-$1.98M$32.95M$3.29B$266.51M7 Day Performance-7.55%2.88%1.28%0.45%1 Month Performance-2.97%9.38%8.56%5.05%1 Year Performance1,401.90%2.44%61.19%26.03% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS PharmaceuticsN/A$1.96-1.5%N/A+1,401.9%$7.05MN/A0.006News CoverageITRMIterum Therapeutics2.8163 of 5 stars$0.66-2.6%$9.00+1,265.7%-37.2%$29.52MN/A-0.7810News CoveragePositive NewsShort Interest ↓KZRKezar Life Sciences2.6479 of 5 stars$3.89-1.5%$9.00+131.4%-27.3%$28.44M$7M-0.4060CASICASI Pharmaceuticals3.7888 of 5 stars$2.26-2.2%$4.00+77.0%-64.0%$27.80M$28.54M-0.78180Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionASBPAspire BiopharmaN/A$0.56-2.7%N/AN/A$27.74MN/A0.00N/ACLSDClearside Biomedical2.2354 of 5 stars$0.34-8.6%$4.20+1,150.0%-64.3%$27.48M$1.66M-0.9530PMNPromis Neurosciences2.8313 of 5 stars$0.52-2.9%$4.33+727.0%-66.9%$27.30MN/A-2.515Gap DownDAREDare Bioscience1.9327 of 5 stars$2.03+0.2%$12.00+492.6%-37.1%$27.30M$10K-0.9530News CoverageAnalyst UpgradeTENXTenax Therapeutics1.341 of 5 stars$5.98-0.3%$17.00+184.5%+62.3%$27.25MN/A-6.499BCABBioAtla1.4903 of 5 stars$0.46+1.0%$5.00+987.0%-69.2%$27.01M$11M-0.4260Analyst UpgradeMIRAMIRA Pharmaceuticals3.0581 of 5 stars$1.37-0.4%$17.00+1,145.4%-9.7%$26.03MN/A-2.792Analyst DowngradeShort Interest ↓ Related Companies and Tools Related Companies Iterum Therapeutics Alternatives Kezar Life Sciences Alternatives CASI Pharmaceuticals Alternatives Aspire Biopharma Alternatives Clearside Biomedical Alternatives Promis Neurosciences Alternatives Dare Bioscience Alternatives Tenax Therapeutics Alternatives BioAtla Alternatives MIRA Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLSP) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NLSP Stock Alerts